Bolt Biotherapeutics, Inc.

NasdaqCM:BOLT 株式レポート

時価総額：US$9.5m

Bolt Biotherapeutics マネジメント

マネジメント 基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Willie Quinn

最高経営責任者

US$4.6m

報酬総額

CEO給与比率10.17%
CEO在任期間6yrs
CEOの所有権0.1%
経営陣の平均在職期間2yrs
取締役会の平均在任期間3.9yrs

経営陣の近況

Recent updates

分析記事 • Nov 30

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • May 21

Little Excitement Around Bolt Biotherapeutics, Inc.'s (NASDAQ:BOLT) Revenues As Shares Take 29% Pounding

Bolt Biotherapeutics, Inc. ( NASDAQ:BOLT ) shareholders that were waiting for something to happen have been dealt a...
分析記事 • Mar 15

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
分析記事 • May 13

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
分析記事 • Dec 01

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Aug 26

Bolt Biotherapeutics: A Promised Follow Up

Summary Today, we post a promised follow-up on early stage biotech concern Bolt Biotherapeutics. The company has suffered some setbacks over the past year, but the stock now trades for approximately one-third of the cash on its balance sheet. We update the investment thesis around Bolt Biotherapeutics in the paragraphs below. "Pride is always a better lever against the nobility than reason." - Patrick Rothfuss, The Wise Man's Fear In our first article on biotech name Bolt Biotherapeutics, Inc. (BOLT) back in September of last year, we concluded by saying the company had some "potentially intriguing technology" but it was not investment worthy at the time. We also promised we would check back in on this name to see how it was progressing. Today, we follow up on Bolt Biotherapeutics via the analysis below. Seeking Alpha Company Overview: Bolt Biotherapeutics is headquartered in California. The company is developing drug candidates using its Boltbody immune-stimulating antibody conjugate (ISAC) platform. This technology is being applied to create a new category of immunotherapies that generate a robust anti-tumor immune response by combining the precision of antibody targeting with the strength of the innate and adaptive immune systems. By activating and recruiting myeloid cells, Boltbody ISACs re-program the tumor microenvironment to invoke a new anti-tumor immune response. Company Website Myeloid cells are a group of immune cells that belong to the innate immune system. They consist of cell types known as monocytes, macrophages, dendritic cells, and granulocytes. These cells serve many essential roles in the body's immune system. When these cells are functioning properly, they can stimulate anti-tumor effects in the body. Including the activation of tumor-specific T cells to support durable anti-tumor immune responses and immunological memory. Immunosuppressive factors produced in the tumor microenvironment can impair the normal function of these cells. The stock currently trades around two bucks a share and sports an approximate market capitalization of $75 million. Recent Developments: The biggest news around the company since we last peaked in on it occurred early in December of last year. Bolt Biotherapeutics presented interim clinical data from its Phase 1/2 study of BDC-1001, its lead candidate, at the European Society for Medical Oncology Immuno-Oncology Congress. Early data showed 13 of the 40 tumor evaluable subjects with one durable partial response maintained through 52 weeks and multiple subjects achieving stable disease for >12 weeks. BDC - 1001 is currently in clinical development for the treatment of patients with HER2-expressing solid tumors, including subsets with HER2-low tumors. This data was good enough to support initiation of the combination therapy study with nivolumab, also known by its brand name Opdivo from Bristol-Myers Squibb (BMY). That said, the data did not meet investors' expectations as the market cut the stock in roughly half after interim results from the study became known. Weekly dosing with a study around a combination therapy with Opdivo has begun and should be noted. Company Website The company has one other compound in development currently. It is called BDC-3042. This candidate is a myeloid modulating agonist antibody that reawakens myeloid cells to attack tumor cells. Specifically, BDC-3042 will stimulate a novel target called Dectin-2. This is found in tumor-associated macrophages across a broad range of solid tumors. Stimulating Dectin-2 leads to tumor macrophage reprogramming and anti-cancer activity in the company's preclinical studies. BDC-3042 will target solid tumors with a high unmet lead. However, BDC-3042 is still in the pre-clinical phase and is currently in IND-enabling studies. Analyst Commentary & Balance Sheet: Analysts are mixed on Bolt's prospects at the moment. Morgan Stanley has a Hold rating on the stock. On August 11th, SVP Securities downgraded Bolt from Outperform to Market Perform and slashed its price target in half to $4 a share. SVB's analyst noted he sees "A long road to recovery" following the company's announced discontinuation of second Boltbody candidate BDC-2034, which was previously on track to enter the clinic in 2023. The discontinuation was prompted by non-human primate fatalities observed at mid- to high-dose levels in toxicology studies. That same day, both Stifel Nicolaus ($7 price target) and JonesTrading ($8 price target) maintained Buy ratings on Bolt Biotherapeutics. The company ended the second quarter with just over $220 million in cash and marketable securities on its balance sheet. Bolt burned through around $23 million during the quarter to fund all operations. The company has no long-term debt. Management has put in place measures to conserve cash as was summarized in its second quarter earnings press release.
Seeking Alpha • Aug 10

Bolt Biotherapeutics GAAP EPS of -$0.61 beats by $0.08, revenue of $1.39M beats by $0.89M

Bolt Biotherapeutics press release (NASDAQ:BOLT): Q2 GAAP EPS of -$0.61 beats by $0.08. Revenue of $1.39M beats by $0.89M.
分析記事 • Jul 27

We're Keeping An Eye On Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Apr 12

We're Not Very Worried About Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Dec 03

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Aug 18

Bolt Biotherapeutics: Pioneering A New Class Of Immunotherapies

Bolt has built out a next-generation immunotherapy platform to design biologics for cancers that are not accessible for the current standard-of-care. The company's lead asset, BDC-1001, is expected to complete phase 1 clinical trials later this year creating a window for an opportunistic investment. As the pipeline matures, Bolt will be able to build out their partnerships and transition their business toward a fully-integrated diversified model.
分析記事 • Aug 18

We're Hopeful That Bolt Biotherapeutics (NASDAQ:BOLT) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

CEO報酬分析

Bolt Biotherapeutics の収益と比較して、Willie Quinn の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2026n/an/a

-US$30m

Dec 31 2025US$5mUS$464k

-US$33m

Sep 30 2025n/an/a

-US$43m

Jun 30 2025n/an/a

-US$51m

Mar 31 2025n/an/a

-US$63m

Dec 31 2024US$1mUS$454k

-US$63m

Sep 30 2024n/an/a

-US$65m

Jun 30 2024n/an/a

-US$66m

Mar 31 2024n/an/a

-US$63m

Dec 31 2023US$912kUS$442k

-US$69m

Sep 30 2023n/an/a

-US$71m

Jun 30 2023n/an/a

-US$77m

Mar 31 2023n/an/a

-US$81m

Dec 31 2022US$1mUS$423k

-US$88m

Sep 30 2022n/an/a

-US$95m

Jun 30 2022n/an/a

-US$97m

Mar 31 2022n/an/a

-US$98m

Dec 31 2021US$2mUS$395k

-US$99m

Sep 30 2021n/an/a

-US$102m

Jun 30 2021n/an/a

-US$89m

Mar 31 2021n/an/a

-US$77m

Dec 31 2020US$1mUS$239k

-US$61m

報酬と市場: Willieの 総報酬 ($USD 4.56M ) は、 US市場 ($USD 627.03K ) の同規模の企業の平均を上回っています。

報酬と収益: Willieの報酬は増加しましたが、会社は利益を上げていません。

CEO

Willie Quinn (54 yo)

6yrs
在職期間
US$4,558,368
報酬

Mr. William P. Quinn, also known as Willie, is CEO, President & Director of Bolt Biotherapeutics, Inc. from May 15, 2024. He has been Chief Financial Officer at Bolt Biotherapeutics, Inc. since May 2020 an...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
William Quinn
CEO, CFO6yrsUS$4.56m0.12%
$ 11.4k
Grant Yonehiro
COO & Chief Business Officer2yrsUS$4.01m0.023%
$ 2.2k
Sarah Nemec
Senior VP of Finance & Principal Accounting Officer2yrsデータなし0.049%
$ 4.7k
Michael Alonso
Senior Vice President of Research2yrsデータなしデータなし
Justin Kenkel
Senior Principal Scientistno dataデータなしデータなし
2.0yrs
平均在職期間
54yo
平均年齢

経験豊富な経営陣: BOLTの経営陣は 経験豊富 であると考えられます ( 2年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
William Quinn
CEO, CFO2yrsUS$4.56m0.12%
$ 11.4k
Kathleen LaPorte
Independent Director5.4yrsUS$600.25k0.0031%
$ 296.8
Nicole Onetto
Independent Director4.4yrsUS$310.70k0%
$ 0
Brian O'Callaghan
Independent Chairman4.5yrsUS$448.94k0%
$ 0
Jakob Dupont
Independent Director1.7yrsUS$191.84k0%
$ 0
Laura Berner
Independent Director3.4yrsUS$173.67k0%
$ 0
3.9yrs
平均在職期間
58yo
平均年齢

経験豊富なボード: BOLTの 取締役会 は 経験豊富 であると考えられます ( 3.9年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/24 11:47
終値2026/05/22 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Bolt Biotherapeutics, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6

アナリスト機関
Robert BurnsH.C. Wainwright & Co.
Boris PeakerJonesTrading Institutional Services, LLC
Chad MesserLake Street Capital Markets, LLC